You just read:

EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease

News provided by

EIP Pharma, Inc.

Nov 07, 2019, 07:00 ET